Paper147116
Fast-acting plasmin inhibitor in human plasma.
Collen D and 1 other. Blood, 1978. Cited by 68 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Fast-acting plasmin inhibitor in human plasma. Papers, record 147116. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/147116
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Fibrinolysin | Major topic |
| Cell Transformation, Neoplastic | |
| Chemical Phenomena | |
| Chemistry | |
| Chromatography, Affinity | |
| Chromatography, Gel | |
| Esterases | |
| Female | |
| Fibrinolysis | |
| Glycoproteins | |
| Humans | |
| Male | |
| Peptide Hydrolases | |
| Time Factors |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40,867,572 | Effect of Alpha2-Plasmin Inhibitor C-Terminal Heterogeneity on Clot Lysis and Clot Structure. | Biomolecules | 2025 | https://conductscience.org/library/papers/40867572 | PubMed |
| 39,299,614 | Bivariate genome-wide association study of circulating fibrinogen and C-reactive protein levels. | J Thromb Haemost | 2024 | https://conductscience.org/library/papers/39299614 | PubMed |
| 36,759,279 | Assays to quantify fibrinolysis: strengths and limitations. Communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on fibrinolysis. | J Thromb Haemost | 2023 | https://conductscience.org/library/papers/36759279 | PubMed |
| 35,986,069 | Alterations in the kallikrein-kinin system predict death after heart transplant. | Sci Rep | 2022 | https://conductscience.org/library/papers/35986069 | PubMed |
| 33,426,005 | Alpha2-Antiplasmin: The Devil You Don't Know in Cerebrovascular and Cardiovascular Disease. | Front Cardiovasc Med | 2020 | https://conductscience.org/library/papers/33426005 | PubMed |
| 30,429,724 | Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure. | EJIFCC | 2001 | https://conductscience.org/library/papers/30429724 | PubMed |
| 29,294,343 | Matrix Metalloproteinase-9 Mediates the Deleterious Effects of α2-Antiplasmin on Blood-Brain Barrier Breakdown and Ischemic Brain Injury in Experimental Stroke. | Neuroscience | 2018 | https://conductscience.org/library/papers/29294343 | PubMed |
| 28,710,283 | Amorphous protein aggregates stimulate plasminogen activation, leading to release of cytotoxic fragments that are clients for extracellular chaperones. | J Biol Chem | 2017 | https://conductscience.org/library/papers/28710283 | PubMed |
| 24,383,758 | Decoy plasminogen receptor containing a selective Kunitz-inhibitory domain. | Biochemistry | 2014 | https://conductscience.org/library/papers/24383758 | PubMed |
| 21,700,944 | Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke. | Stroke | 2011 | https://conductscience.org/library/papers/21700944 | PubMed |
| 7,276,224 | Concentration of plasminogen and antiplasmin in plasma and serum. | J Clin Pathol | 1981 | https://conductscience.org/library/papers/7276224 | PubMed |
| 7,199,538 | Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. | J Clin Invest | 1982 | https://conductscience.org/library/papers/7199538 | PubMed |
| 6,907,016 | Affinity-chromatographic purification of human alpha 2-antiplasmin. | Biochem J | 1980 | https://conductscience.org/library/papers/6907016 | PubMed |
| 6,291,058 | Synthesis and secretion of alpha 2-plasmin inhibitor by established human liver cell lines. | Proc Natl Acad Sci U S A | 1982 | https://conductscience.org/library/papers/6291058 | PubMed |
| 3,115,654 | A lysine-binding protein in SLE sera inhibits the binding of immune complexes to normal erythrocyte CR1 (complement receptor type 1). | Clin Exp Immunol | 1987 | https://conductscience.org/library/papers/3115654 | PubMed |
| 2,445,779 | alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder. | J Clin Invest | 1987 | https://conductscience.org/library/papers/2445779 | PubMed |
| 293,745 | Structural studies of human IgD: isolation by a two-step purification procedure and characterization by chemical and enzymatic fragmentation. | Proc Natl Acad Sci U S A | 1979 | https://conductscience.org/library/papers/293745 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| PLG | 5,340 | PubTator's text mining | https://conductscience.org/library/genes/5340 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/147116
GET https://conductscience.org/api/papers/v1/147116/authors